New hope for elderly myeloma patients: drug combo aims to deepen remission without transplant

This phase 3 study tests whether adding the drug isatuximab to a standard two-drug regimen (lenalidomide and dexamethasone) works better with or without a third drug (bortezomib) for newly diagnosed multiple myeloma. The study includes 270 non-frail patients aged 65 to 79 who are not eligible for a stem cell transplant. The main goal is to see how many patients achieve a very low level of cancer cells (minimal residual disease) after 18 months of treatment.